People · Operator
Named in public records as an officer, director or promoter · active 2011–2025 · Other Technology, Software / Tech, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| eTouches, Inc. | — | Other Technology | Series B | $61.6M | $609.1M | 2012 |
| CloudCheckr Inc. | — | Other Technology | Series C | $50.4M | $1.6B | 2017 |
| simPRO Holdings, Inc. | — | Other Technology | Series B | $47.0M | $500.7M | 2016 |
| Mytonomy, Inc. | — | Other Technology | Series B | $35.6M | $534.5M | 2021 |
| Matchbin Inc | — | Other Technology | Series A | $22.0M | $207.3M | 2011 |
| STACK Construction Technologies, Inc. | — | Software / Tech | Series B | $22.0M | $15.3M | 2025 |
| Cytrx Corp | — | Pharmaceuticals | Series A | $9.5M | $160.5M | 2016 |
| Tripleseat Software Holdings, Inc. | — | Software / Tech | Series A | $9.0M | $55.5M | 2017 |
| Aviso Partners, Inc. | — | Other Technology | Seed | $1.1M | $36.6M | 2017 |
Benjamin Levin at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Benjamin Levin on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Charles Chen | 2 | 4 |
| Gavin Christensen | 1 | 23 |
| Michael Levinthal | 1 | 10 |
| Scott Petty | 1 | 9 |
| Peter Longo | 1 | 8 |
| Gautam Gupta | 1 | 7 |
| Pauline Murphy | 1 | 6 |
| Geoff Schneider | 1 | 6 |
| Charles Wilson | 1 | 5 |
| Aaron Klein | 1 | 5 |
| Wayne Cantwell | 1 | 4 |
| Stephen Snowdy | 1 | 4 |
| Nicholas Pappas | 1 | 4 |
| Richard Wilmot | 1 | 4 |
| Eric Larsen | 1 | 4 |
| Matthew Fish | 1 | 3 |
| Cheryl Cohen | 1 | 3 |
| Douglas Groh | 1 | 3 |
| Julian Castelli | 1 | 3 |
| Steven A. Kriegsman | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.